These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 26350263)

  • 21. Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study).
    Robak T; Jamroziak K; Gora-Tybor J; Stella-Holowiecka B; Konopka L; Ceglarek B; Warzocha K; Seferynska I; Piszcz J; Calbecka M; Kostyra A; Dwilewicz-Trojaczek J; Dmoszyñska A; Zawilska K; Hellmann A; Zdunczyk A; Potoczek S; Piotrowska M; Lewandowski K; Blonski JZ
    J Clin Oncol; 2010 Apr; 28(11):1863-9. PubMed ID: 20212251
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fludarabine and cyclophosphamide using an attenuated dose schedule is a highly effective regimen for patients with indolent lymphoid malignancies.
    Tam CS; Wolf MM; Januszewicz EH; Prince HM; Westerman D; Seymour JF
    Cancer; 2004 May; 100(10):2181-9. PubMed ID: 15139062
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia.
    Bosch F; Abrisqueta P; Villamor N; Terol MJ; González-Barca E; Ferra C; González Diaz M; Abella E; Delgado J; Carbonell F; García Marco JA; Escoda L; Ferrer S; Monzó E; González Y; Estany C; Jarque I; Salamero O; Muntañola A; Montserrat E
    J Clin Oncol; 2009 Sep; 27(27):4578-84. PubMed ID: 19704063
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Frontline treatment of follicular lymphoma with fludarabine, cyclophosphamide, and rituximab followed by rituximab maintenance: toxicities overcome its high antilymphoma effect. Results from a Spanish Cooperative Trial (LNHF-03).
    Tomás JF; Montalbán C; De Sevilla AF; Martínez-López J; Díaz N; Canales M; Martínez R; Sánchez-Godoy P; Caballero MD; Peñalver J; Prieto E; Salar A; Burgaleta C; Queizán JA; Bajo R; De Oña R; De La Serna J
    Leuk Lymphoma; 2011 Mar; 52(3):409-16. PubMed ID: 21275633
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL.
    Johnson S; Smith AG; Löffler H; Osby E; Juliusson G; Emmerich B; Wyld PJ; Hiddemann W
    Lancet; 1996 May; 347(9013):1432-8. PubMed ID: 8676625
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.
    Flinn IW; Neuberg DS; Grever MR; Dewald GW; Bennett JM; Paietta EM; Hussein MA; Appelbaum FR; Larson RA; Moore DF; Tallman MS
    J Clin Oncol; 2007 Mar; 25(7):793-8. PubMed ID: 17283364
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine.
    Montillo M; Cafro AM; Tedeschi A; Brando B; Oreste P; Veronese S; Rossi V; Cairoli R; Pungolino E; Morra E
    Haematologica; 2002 Jul; 87(7):695-700; discussion 700. PubMed ID: 12091119
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia.
    Hopfinger G; Busch R; Pflug N; Weit N; Westermann A; Fink AM; Cramer P; Reinart N; Winkler D; Fingerle-Rowson G; Stilgenbauer S; Döhner H; Kandler G; Eichhorst B; Hallek M; Herling M
    Cancer; 2013 Jun; 119(12):2258-67. PubMed ID: 23512246
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II trial of sequential therapy with fludarabine followed by cyclophosphamide, mitoxantrone, vincristine, and prednisone for low-grade follicular lymphomas.
    Rohatgi N; LaRocca RV; Bard V; Sethuraman G; Foon KA
    Am J Hematol; 2002 Jul; 70(3):181-5. PubMed ID: 12111762
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experience.
    Herishanu Y; Goldschmidt N; Bairey O; Ruchlemer R; Fineman R; Rahimi-Levene N; Shvidel L; Tadmor T; Ariel A; Braester A; Shapiro M; Joffe E; Polliack A;
    Haematologica; 2015 May; 100(5):662-9. PubMed ID: 25661442
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Conventional dose fludarabine-based regimens are effective but have excessive toxicity in elderly patients with refractory chronic lymphocytic leukemia.
    Shvidel L; Shtalrid M; Bairey O; Rahimi-Levene N; Lugassy G; Shpilberg O; Polliack A; Berrebi A;
    Leuk Lymphoma; 2003 Nov; 44(11):1947-50. PubMed ID: 14738148
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Efficacy of chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia].
    Fang C; Xu W; Xu M; Hong M; Zhu DX; Zhu HY; Wu YJ; Fan L; Qiao C; Zhuang Y; Miao KR; Liu P; Li JY
    Zhonghua Xue Ye Xue Za Zhi; 2011 Jan; 32(1):3-7. PubMed ID: 21429392
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sensitization of B-cell chronic lymphocytic leukemia cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligodeoxynucleotides.
    Decker T; Hipp S; Kreitman RJ; Pastan I; Peschel C; Licht T
    Blood; 2002 Feb; 99(4):1320-6. PubMed ID: 11830482
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II study of fludarabine and alpha-interferon in patients with low-grade non-Hodgkin's lymphoma.
    Morris GJ; Millenson MM; Padavic-Shaller K; Wang H; Rogatko A; Clyde J; Boyd RL; Yeslow G; Halbherr T; Schilder RJ; Smith MR
    Haematologica; 2004 Dec; 89(12):1484-91. PubMed ID: 15590399
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia.
    Tsimberidou AM; Kantarjian HM; Cortes J; Thomas DA; Faderl S; Garcia-Manero G; Verstovsek S; Ferrajoli A; Wierda W; Alvarado Y; O'Brien SM; Albitar M; Keating MJ; Giles FJ
    Cancer; 2003 Apr; 97(7):1711-20. PubMed ID: 12655528
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Salvage chemotherapy using a combination of fludarabine and cyclophosphamide for refractory or relapsing indolent and aggressive non-Hodgkin's lymphomas.
    Lossos IS; Paltiel O; Polliack A
    Leuk Lymphoma; 1999 Mar; 33(1-2):155-60. PubMed ID: 10194133
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rational design of low immunogenic anti CD25 recombinant immunotoxin for T cell malignancies by elimination of T cell epitopes in PE38.
    Mazor R; Kaplan G; Park D; Jang Y; Lee F; Kreitman R; Pastan I
    Cell Immunol; 2017 Mar; 313():59-66. PubMed ID: 28087047
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years.
    Candoni A; Martinelli G; Toffoletti E; Chiarvesio A; Tiribelli M; Malagola M; Piccaluga PP; Michelutti A; Simeone E; Damiani D; Russo D; Fanin R
    Leuk Res; 2008 Dec; 32(12):1800-8. PubMed ID: 18621416
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [A clinical observation of fludarabine-containing regimens in the treatment of low grade non-Hodgkin's lymphoma].
    Lü SQ; Yang JM; Song XM; Chen L; Zhang WP; Ni X; Xu XQ; Wang JM
    Zhonghua Zhong Liu Za Zhi; 2007 Sep; 29(9):710-2. PubMed ID: 18246806
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia.
    Mato AR; Foon KA; Feldman T; Schuster SJ; Svoboda J; Chow KF; Valentinetti M; Mrkulic M; Azzollini K; Gadaleta G; Bhattacharyya PK; Zenreich J; Pascual LN; Yannotti K; Kdiry S; Howlett C; Strelec L; Porter D; Bejot C; Goy A
    Am J Hematol; 2015 Jun; 90(6):487-92. PubMed ID: 25691474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.